High BMI May Cut Overall Survival in HER2 + Metastatic Breast Cancer

BMI had no impact on progression - free survival to first - line chemotherapy
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Gynecology, Oncology, Journal, Source Type: news

Related Links:

Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Authors: Montemurro F, Nuzzolese I, Ponzone R Abstract Introduction: The administration of chemotherapy before (neoadjuvant), rather than after surgery (adjuvant) in early breast cancer has been considered an optional strategy for patients with operable breast cancer. We reviewed this concept considering recent results in the field.Areas covered: Herein, the authors cover neoadjuvant chemotherapy with or without biologics in triple-negative and HER2-positive operable breast cancer with a focus on rates of complete pathological remission (pCR) in the breast and axilla. The impact of the CREATE X and KATERINE randomi...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
To determine the impact of radiation therapy (XRT) in addition to trastuzumab (TZB) adjuvant chemotherapy for HER2+ breast cancer on left ventricular systolic function, we assessed demographics, oncologic treatment history including XRT exposure, and serial measurements of left ventricular ejection fraction (LVEF) in 135 consecutively identified women receiving TZB for treatment of adjuvant breast cancer. Longitudinal mixed effects models were fit to identify baseline to treatment changes in LVEF among those receiving TZB with or without concomitant anthracycline or XRT.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
British Journal of Cancer, Published online: 02 April 2020; doi:10.1038/s41416-020-0815-9Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study
Source: British Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
Conditions:   Anatomic Stage I Breast Cancer AJCC v8;   Anatomic Stage IA Breast Cancer AJCC v8;   Anatomic Stage IB Breast Cancer AJCC v8;   Anatomic Stage II Breast Cancer AJCC v8;   Anatomic Stage IIA Breast Cancer AJCC v8;   Anatomic Stage IIB Breast Cancer AJCC v8 ;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJC...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Authors: Zhang L, Li Z, Zhang J, Wu Y, Zhu Y, Tong Z Abstract The purpose of the present study was to analyze the clinical and pathological characteristics, treatment, and prognosis of de novo metastatic breast cancer (DnMBC). Information regarding 1,890 patients treated for advanced breast cancer at the Tianjin Medical University Cancer Hospital between January 2008 to December 2017 was collected. Clinicopathological characteristics, treatments and outcomes of these patients were compared using the chi-square test, log-rank test, and Cox regression analysis. A total of 171 patients were diagnosed with DnMBC. The m...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Authors: Nakazawa Y, Nakazawa S, Kurozumi S, Ogino M, Koibuchi Y, Odawara H, Oyama T, Horiguchi J, Fujii T, Shirabe K Abstract Biomarkers that can accurately predict treatment response are required for indicating optimal neoadjuvant treatments. The current study assessed the predictive value of secreted protein acidic and rich in cysteine (SPARC) mRNA expression for the response to neoadjuvant nab-paclitaxel (nab-PTX) therapy in patients with breast cancer. It was hypothesized that SPARC expression can affect the response to albumin-bound taxanes, including nab-PTX since SPARC binds albumin with a high affinity. Pr...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
ConclusionsDespite similar long-term efficacy and safety profile, the higher breast conservation rate in the TC6 group suggests that preoperative chemotherapy without an anthracycline may benefit patients with HR-positive HER2-negative BC.Trial registrationUMIN000003283https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003873.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
In conclusion, HER2 codon 655 A>G was an independent predictive factor for increased cardiotoxicity risk in HER2-positive breast cancer patients undergoing EC-D-T adjuvant chemotherapy. PMID: 32211111 [PubMed]
Source: International Journal of Clinical and Experimental Pathology - Category: Pathology Authors: Tags: Int J Clin Exp Pathol Source Type: research
Authors: Gunawan I, Hatta M, Benyamin AF, Islam AA Abstract OBJECTIVE: Hypoxia-associated biomarkers profiling may provide information for prognosis, staging, and subsequent therapy. We aim to evaluate whether the quantitative gene and protein expression of hypoxic response tumor markers - carbonic anhydrase IX (CAIX) and hypoxia- inducible factor 1 alpha (HIF1A) - may have a role in predicting survival in advanced breast cancer of Indonesian population. METHODS: Tumor tissues and peripheral blood samples were collected from treatment - naïve locally advanced (LABC) or metastatic breast cancer patients (MB...
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | HER2